Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 905 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ara C Clear all
Recruiting Phase 1 Interventional

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

NCT04659616
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Cytarabine, Daunorubicin, Electrocardiography, Pemigatinib
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation

NCT00591630
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Lymphoma
Interventions
Zevalin, Carmustine, Etoposide, Cytarabine, Melphalan, Rituximab, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 15, 2026, 4:04 PM EDT
Active, not recruiting Phase 2 Interventional

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

NCT03147612
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Filgrastim, Methotrexate, Pegfilgrastim, Ponatinib, Rituximab, Vincristine
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

NCT04250051
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Filgrastim, Fludarabine, Fludarabine Phosphate, Ivosidenib, Idarubicin
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

NCT07008638
View directory record Official record
Conditions
Acute Myeloid Leukemia, TP53
Interventions
Bortezomib, CPX-351
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Active, not recruiting No phase listed Observational

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

NCT04263181
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Peripheral blood draw, Bone marrow aspirate, Buccal swab
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

NCT00774046
View directory record Official record
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Ara-C, Mitoxantrone, Etoposide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
10 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

NCT00003783
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
51
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT02545283
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cytarabine, Idasanutlin, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Great Neck, New York • Hawthorne, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

NCT02306291
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
GMI-1271, Mitoxantrone, Etoposide, Cytarabine, Idarubicin
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2019 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01238211
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Core Binding Factor Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
65
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia

NCT01960387
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Clofarabine, Cytarabine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

NCT00002704
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, asparaginase, cyclophosphamide, daunorubicin hydrochloride, dexamethasone, etoposide, leucovorin calcium, liposomal cytarabine, mercaptopurine, mesna, methotrexate, therapeutic hydrocortisone, thiotepa, vincristine sulfate, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 20 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Not applicable Interventional Results available

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NCT02121418
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Untreated Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Decitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Bozeman, Montana • Kennewick, Washington • Kirkland, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

NCT00515788
View directory record Official record
Conditions
Neoplastic Meningitis
Interventions
DepoCyt, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2012 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

NCT02779283
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
Drug · Device · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

NCT02044796
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride
Drug · Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

NCT00238368
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT01408160
View directory record Official record
Conditions
Adult B Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions
Cytarabine, Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Biological · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
The Bronx, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 15, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00335140
View directory record Official record
Conditions
Lymphoma
Interventions
Rituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate, Procarbazine, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
68
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 3 Interventional Results available

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)

NCT00329030
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Non-Hodgkin
Interventions
Autologous transplantation using rituxan/BEAM, Autologous transplantation using Bexxar/BEAM
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
36
States / cities
New Haven, Connecticut • Gainesville, Florida • Miami, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 15, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

NCT00669877
View directory record Official record
Conditions
Burkitt's Lymphoma, Burkitt'S-like Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone, G-CSF, Cytarabine, Methotrexate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 15, 2026, 4:04 PM EDT